If You’re The Kind of Person Who Loves Research, Science and Proof…

We can confidently tell you no other natural health care product has anywhere near the science that Prodantim has.

Below you will find:

  • Validated research on Google Scholar and PubMed
  • Testimonials from Health Care Professionals
  • The Patents
  • The Science and Peer-Reviewed Studies 

“Our results suggest that suppression of p53 and induction of MnSOD may play an important role in the tumor suppressive activity of Protandim.”

– National Library of Medicine

Your Own Research on Google Scholar and PubMed

The LifeVantage products and Protandim naturally re-activate the body’s antioxidants production system (NRF2 and NRF1 pathways), and are clinically proven to significantly reduce damaging oxidative stress levels.

In this short video, you’ll see why Health Care Professionals are excited about Protandim Nrf2.

Did you know it’s not possible to patent a herbal or natural product?

So how can Protandim Nrf2 have 13 registered patents?

It’s because the blend of ingredients does something that the individual ingredients can’t do on their own. It’s called SYNERGY!

USA PATENTS

US Patent 9,265,808
Compositions for alleviating inflammation and oxidative stress in a mammal

US Patent 7,579,026
Methods for enhancing antioxidant enzyme activity and reducing c-reactive protein levels

US Patent 8,435,574
Compositions for alleviating inflammation and oxidative stress in a mammal

US Patent 7,384,655
Preparation of compositions to alleviate inflammation and oxidative stress in a mammal

US Patent 8,221,805
Compositions for alleviating inflammation and oxidative stress in a mammal

US Patent 7,241,461
Compositions for alleviating inflammation and oxidative stress in a mammal

US Patent 7,923,045
Compositions for alleviating inflammation and oxidative stress in a mammal

INTERNATIONAL PATENTS

AUSTRALIAN Patent 2005229008
Compositions for alleviating inflammation and oxidative stress in a mammal

CANADIAN Patent 2,560,826
Antioxidant-promoting herbal extract compositions for alleviating oxidative stress in a mammal

CHINESE Patent ZL200580016510.7
Compositions for alleviating inflammation and oxidative stress in a mammal

INDIAN Patent 248562
Compositions for alleviating inflammation and oxidative stress in a mammal

JAPANESE Patent 5507645
Compositions for alleviating inflammation and oxidative stress in a mammal

EUROPEAN Patent 1740196
Compositions for alleviating inflammation and oxidative stress in a mammal

PEER-REVIEWED ARTICLES REFERENCING PROTANDIM

HUMAN STUDIES:

  1. Nelson (2006)—Healthy humans (120 days)
    1. Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM. The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy. Radical Biol Med 2006; 40(2):341-347.
  2. Burnham (2012)—Humans with alcohol use disorders (1 week)
    1. Burnham EL, McCord JM, Bose S, Brown LA, House R, Moss M, Gaydos J. Protandim does not influence epithelial permeability or intrapulmonary oxidative stress in human subjects with alcohol use disorders. Am J Physiol Lung Cell Mol Physiol 2012; 302(7):L688-L699.
  3. Scalzo (2014)—Healthy Overweight humans & JP Protandim (30 days)
    1. Scalzo R, Davis J, Beals J, Biela L, Giordan G, Paris H, Miller BF, Hamilton KL, Bell C. Oxidative stress is decreased with short-term Protandim use when Piperine is substituted for Ashwagandha (LB399). FASEB J 2014; 28(1 Suppl):LB399.
  4. Ueberschlag (2016) – Runners (90 days)
    1. Ueberschlag SL, Seay JR, Roberts AH, DeSpirito PC, Stith JM, Folz RJ, Carter KA, Weiss EP, Zavorsky GS. The effect of Protandim® supplementation on athletic performance and oxidative blood markers in runners. PLosOne 2016; 11(8):e0160559
  5. Konopka (2017) Influence of NRF2 activators on subcellular skeletal muscle protein
    1. Konopka AR, Laurin JL, Musci RV, Wolff CA, Reid JJ, Biel MA, Zhang Q, Peelor, FE 3rd, Melby CL, Hamilton KL, Miller BF. Influence of NRF2 activators on subcellular skeletal muscle protein and DNA synthesis rates after 6 weeks of milk protein feeding in older adults. Gero Sci 2017; 39(2):175-186.

LABORATORY STUDIES IN VITRO:

  1. Velmurugan (2009)—Mice MIN6 pancreatic beta-cells
    1. Velmurugan K, Alam J, McCord JM, Pugazhenthi S. Synergistic induction of heme oxygenase-1 by the components of the antioxidant supplement Protandim. Free Radic Biol Med 2009; 46(3):430-440.
  2. Robbins (2010)—In Vitro (Animals see below)
    1. Robbins D, Gu X, Shi R, Liu J, Wang F, Ponville J, McCord JM, Zhao Y. The chemopreventive effects of Protandim: modulation of p53 mitochondrial translocation and apoptosis during skin carcinogenesis. 2010. PLosOne 2010; 5(7):e11902.
  3. Hybertson (2011) – in vitro, NRF2 gene expression
    1. Hybertson BM, Gao B, Bose SK, McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Molecular Asp Med 2011; 32(4):234-246.
  4. Joddar (2011)—Human saphenous veins
    1. Joddar B, Reen RK, Firstenberg MS, Varadharaj S, McCord JM, Zweier JL, Gooch KJ. Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway. Free Radical Biol Med 2011; 50(6):700-709.
  5. Donovan (2012) Phytochemical Activation of NRF2
    1. Donovan EL, McCord JM, Reuland DJ, Miller BF, Hamilton KL. Phytochemical activation of Nrf2 protects human coronary artery endothelial cells against an oxidative challenge. Oxid Med Cellular Longevity 2012; Article ID:132931 (9 pages).
  6. Dugan (2012)—Breast cancer cells
    1. Dugan A, Carroll-Turpin M, Crooks S, Zhang S, Mathis M, Kleiner-Hancock HE. Comparison of the dietary supplement Protandim and 4-hydroxytamoxifen on pre-malignant human breast cancer cells in 3D Culture. The FASEB J 2012; 26 (1_Meeting Abstracts), 1118-1115. ABSTRACT
  7. Lisk (2013)—Rats & acute mountain sickness (Animal see below)
    1. Lisk C, McCord J, Bose S, Sullivan T, Loomis Z, Nozik-Grayck E, Schroeder T, Hamilton K, Irwin DC. Nrf2 activation: a potential strategy for the prevention of acute mountain sickness. Free Rad Biol Med 2013; 63:264-273.
  8. Reuland (2013)— Heart muscle cells
    1. Reuland DJ, Khademi S, Castle CJ, Irwin DC, McCord JM, Miller BF, Hamilton KL. Upregulation of phase II enzymes through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress. Free Rad Biol Med 2013; 56:102-111.
  9. Lim (2016) – Rat brain cells (oligodendrocytes)
    1. Lim, JL, van der Pol SM, Baron W, McCord JM, de Vries HE, van Horssen J. Protandim protects oligodendrocytes against an oxidative insult. Antioxidants2016; 5:30.
  10. Abusarah (2017) – Human cartilage cells (Animal see below)
    1. Abusarah J, Benabdoune H, Shi Q, Lussier B, Martel-Pelletier J, Malo M, Fernandes JC, de Souza FP, Fahmi H, Benderdour M. Elucidating the role of Protandim and 6-gingerol in protection against osteoarthritis. J Cell Biochem 2017; 118(5):1003-1013.
  11. Chevreau (2017) – Primary human small intestinal epithelial cells (Extended Abstract)
    1. Chevreau N. Protandim treatment causes reversible nuclear translocation of Nrf2 and activation of the antioxidant response element. J Int Soc Antioxidants2017; 3(3):11865. DOI 10.18143/JISANH_v3i3_1186. (extended abstract)

ANIMAL:

  1. Bogaard (2009)—Rats heart muscles cells
    1. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009; 120(20): 1951-1960.
  2. Liu (2009)—Mice with skin cancer
    1. Liu J, Gu X, Robbins D, Li G, Shi R, McCord JM, Zhao Y. Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model. PLosOne 2009; 4(4): e5284.
  3. Qureshi (2010)—Mice with muscular dystrophy
    1. Qureshi MM, McClure WC, Arevalo NL, Rabon RE, Mohr B, Bose SK, McCord JM, Tseng BS. The dietary supplement Protandim® decreases plasma osteopontin and improves markers of oxidative stress in muscular dystrophy Mdx mice. J Diet Supplements 2010; 7(2):159-178.
  4. Cheatam (2015) – Mice and hearing loss
    1. Cheatam MA, Edge RM, Homma K, Leserman EL, Dallos P, Zheng J. Prestin-dependence of outer hair cell survival and partial rescue of outer hair cell loss in PrestinV499G/Y501H Knockin Mice. PlosOne 2015; 10(12):e0145428.
  5. Strong (2016) – Mice and longevity
    1. a. Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, De Magalhaes JP, Marinez PA, McCord JM, Miller BF, Muller M, Nelson JF, Ndukum J, Rainger G, Richardson A, Sabatini DM, Salmon AB, Simpkins JW, Steegenga WT, Nadon NL, Harrison DE. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer. Aging Cell 2016; 12496.
  6. Bruns (2018) – Mice exercise and antioxidant production
    1. Bruns DR, Ehrlicher SE, Khademi S, Biela LM, Peelor FF 3rd, Miller BF, Hamilton KL. Differential effects of vitamin C or protandim on skeletal muscle adaptation to exercise. J Appl Physiol 2018; 125:661-671.
  7. Priestley (2019) – Rats/Hamsters and high salt diet
    1. Priestley JRC, Fink KE, McCord JM, Lombard JH. NRF2 activation with Protandim attenuates salt-induces vascular dysfunction and microvascular rarefaction. Microcirculation 2019; 26(7)e12575. DOI: 10.1111/micc.12575.
  8. Song (2019) – Rats absorption/tissue distribution
    1. Song Y, Sun H, Xiao J, Wang F, Ding Y, Zhao J, Bai J, Cheng L, Gao K, Liu M, Guo Q, Zhang Y, Gao W, Jia Y, Wen A. Development of a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for simultaneously determination of epigallocatechin-3-gallate, silibinin, and curcumin in plasma and different tissue after oral dosing of Protandim in rats and its application in pharmacokinetic and tissue distribution studies.J Pharm Biomed Anal 2019; 170:54-62.
  9. Robbins (2010)—In Vitro -Animal
    1. Robbins, D., et al. (2010). The chemopreventive effects of Protandim: Modulation of p53 mitochondrial translocation and apoptosis during skin carcinogenesis. PLoS One 5(7): e11902.
  10. Lisk (2013)—Rats & acute mountain sickness
    1. Lisk C, McCord J, Bose S, Sullivan T, Loomis Z, Nozik-Grayck E, Schroeder T, Hamilton K, Irwin DC. Nrf2 activation: a potential strategy for the prevention of acute mountain sickness. Free Rad Biol Med 2013; 63:264-273.
  11. Abusarah (2017) – Mice and OA
    1. Abusarah J, Benabdoune H, Shi Q, Lussier B, Martel-Pelletier J, Malo M, Fernandes JC, de Souza FP, Fahmi H, Benderdour M. Elucidating the role of Protandim and 6-gingerol in protection against osteoarthritis. J Cell Biochem 2017; 118(5):1003-1013.

SCIENTIFIC REVIEWS:

  1. Hybertson (2011)—Potential of Nrf2 activation.
    1. Hybertson BM, Gao B, Bose SK, McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Asp Med 2011; 32(4-6):234-246.
  2. Robbins (2011)—MnSOD and skin cancer
    1. Robbins D, Zhao Y. The role of manganese superoxide dismutase in skin cancer. Enzyme Res 2011; Article ID409295, 7 pages. doi:10.4061/2011/409295
  3. Davis (2012)—Antioxidants and oral care
    1. Davis, K. Understanding antioxidants: using various arsenals to impact the oral environment. Dentistry Today 2012; 31(11):92-94.
  4. Reuland (2013)—Attenuation of cardiovascular disease
    1. Reuland DJ, McCord JM, Hamilton KL. The role of Nrf2 in the attenuation of cardiovascular disease. Exerc Sport Sci Rev 2013; 41(3):162-168.
  5. Voelkel (2013)—Pulmonary artery hypertension
    1. Voelkel NF, Bogaard HJ, Husseini A, Farkas L, Gomez-Arroyo J, Natarajan R. Antioxidants for the treatment of patients with severe angioproliferative pulmonary hypertension? Antioxid Redox Signal 2013; 18(14):1810-1817.
  6. Gao (2014)—The clinical potential of Nrf2 activation
    1. Gao B, Doan A, Hybertson BM. The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders. Clinl Pharmacol 2014; 6:19-34.
  7. Pall (2015)- Nrf2 a master regulator
    1. Pall ML, Levine S. Nrf2, a master regulator of detoxification and also antioxidant, anti-inflammatory and other cytoprotective mechanisms, is raised by health-promoting factors. Acta Physiol Sinica 2015; 67(1):1-18

SCIENTIFIC PRESENTATIONS:

  1. Talbott (2015) “The Keap1/Nrf2 Pathway in Health and Disease” at Biochemical Society – January 6-8, 2015 at Cambridge University, United Kingdom
  2. Chevreau N. (2016). Oral presentation – ASN, San Diego, CA.
    1. Protandim treatment causes reversible nuclear translocation of Nrf2 and activation of the antioxidant response element. -> paper published above #16.

Click Here to Try The Products